It can be shown that treatment bringing back independence is less costly than the nursing homes and medical staff.

$AVXL This may show why Anavex is definitely on the right path by using patients personal genetics to determine dosage.

Pill = best possible treatment course.

Many claim him to be selfish and unconcerned with others, I see a different Missling, with humility and a deep concern for patients who are suffering.

Half the patients improved over baseline over 1 year.

Blarcamesine’s Phase III clinical trials show similar levels of significant improvement in communication and interaction, as patients had statistically significant improvement in the RSBQ primary endpoint of 72.2% compared to 38.5% on placebo. .

And better still for just those 85% carrying the normal SigmaR1 gene as well as for APOE2 and 3 patients.

new clinical trial results show great promise for treating early Alzheimer’s, giving renewed hope for effective treatments.

Anavex has over 760 patients that have taken it without any significant issues. .

$SAVA “Treatment also eased depression and dementia-related behaviors in patients, two exploratory trial goals, and simufilam was found to be safe and well tolerated.”

This will bring in billions of revenue and it will make the life quality longer for AD patients.

This sub-set of patients improved -4.96 mean points on ADAS-Cog from baseline to month 12.

CURING LEUKEMIA isn't a fly by night thing with Gamma T Cells and they already have ONE COMPLETE RESPONSE curing someone in Stage 4 nonresponsive to other treatments!

$SAVA this is going to be game changer and first drug to give some relief to AD patients … and will make $BIIB poison AD pills an obsolete

The high number of the patients that went into CMS (which is 80% complete) is reassuring.

but reverses cognitive decline and improves quality of life for the patient AND the FAMILY!

but mostly new hope for all the families and patients with AZ.

Testing still continues, so in my way of thinking the real-world results in patients must be nothing short of excellent.

The introduction of Briumvi reduces the infusion time to one hour, shortening the patients’ time spent in a clinical setting and allowing them to enhance their quality of life.”

In pooled post hoc analyses of ULTIMATE I and II, ublituximab was associated with significant treatment benefit across multiple efficacy measures at Week 96 versus teriflunomide in participants who had not received prior DMT.

ATNM just published very good data from their P3 trail which is great news for Acute myeloid leukemia patients.

Remember that we are ultimately at the beginning of commercialization and quite possible the safest spot to be with the current facts on our superior Briumvi treatment and best pricing for market share penetration.

beyond TG doing well, and us all making a ton of profit, i genuinely hope that this is the answer a lot of MS patients need to help them navigate & improve their illness.

Getting the best available treatment for the lowest price is a no brainer.

We have built what we consider to be a best-in-class team to support this launch, as well as a robust patient support program designed to aid in accessing BRIUMVI at all points through the treatment journey.

They're FDA approved, have the best in class treatment, and is more affordable than the others.

Major upgrade for patients and infusion centers -No major health threats like breast cancer or sever liver damage like main competition

$TGTX possibly the best therapy available for MS patients that exists today!